316 results about "Fibrin" patented technology

The invention relates to the technical field of tumor biomedical engineering and organ chips, in particular to a vascularized gastric cancer organ chip and a preparation method thereof.The chip is composed of an integrated micro-fluidic main body, an annular micro-column array and an optical sealing film, and a central culture cavity is divided into a tumor area and a blood vessel area by micro-columns; the preparation method comprises the following steps: injecting a fibrous protein solution containing human umbilical vein endothelial cells and cancer-related fibroblasts into a vascular region, and adding thrombin for in-situ gelation to form a pre-vascularized network; the method comprises the following steps: mixing a patient-derived gastric cancer organ with a methacrylic acid esterified gelatin pre-polymerized solution, injecting the mixture into a tumor area, and carrying out photo-crosslinking immobilization; culturing for 7-14 days under the dynamic perfusion condition of a mixed culture medium to obtain a three-dimensional gastric cancer organ model containing a capillary network; the method is expected to be used for rapid, low-cost and high-throughput screening of chemotherapy or anti-angiogenesis drugs and accurate prediction of individual curative effects of patients.

The invention discloses a plasmin lumbrukinase peptide dietary therapy formula suitable for rehabilitation of cardiovascular and cerebrovascular diseases, blood circulation promoting, blood stasis removing, thrombolysis, collateral dredging and microcirculation improving, and relates to the technical field of medicine and food homology dietary therapy. Soybean protein isolate and earthworm protein are used as core thrombolytic active raw materials, isomaltooligosacharide, xylitol, German Jilida collagen peptide, soybean peptide powder, Belgian imported inulin, red yeast rice and natto powder are compounded, microcrystalline cellulose and magnesium stearate are used as auxiliary materials, and probiotics / metabiotics strains such as rhamnolactobacilli JYLR-005 and the like can be selectively added. The raw materials have a synergistic effect through precise matching, plasmin and lumbrukinase peptide in earthworm protein can directly dissolve thrombus fibrin, natto powder and red yeast rice assist in lowering lipid and dissolving thrombus, multiple active peptides and prebiotics regulate intestinal microecology to improve microcirculation of the whole body, probiotics / metabiotics further strengthen the metabolic capacity of the body, no chemical medicine is added in the whole process, and the traditional Chinese medicine composition is free of toxic and side effects and free of toxic and side effects. The safety is high; the dietary therapy composition can achieve postoperative rehabilitation conditioning of cardiovascular and cerebrovascular diseases through daily consumption, effectively promote blood circulation to remove blood stasis, dissolve thrombus and dredge collaterals, improve microcirculation and relieve various discomfort caused by blood vessel clogging, raw materials are easy to obtain, compatibility is scientific, and the dietary therapy composition is suitable for large-scale production and popularization.

An oral care composition with retinoid compound, amino acid, and / or olive oil. An oral care composition with retinoid compound, a pentapeptide, such as palmitoyl KTTKS [SEQ ID NO. 2], and / or an olive oil. Methods of preventing gingival recession, stopping gingival recession, reversing gingival recession, decrease gum recession, increase gingival barrier protection, promoting collagen synthesis, promoting extracellular matrix synthesis, increasing gum resilience, increasing epidermal thickness and / or promoting fibrillin synthesis, in an oral cavity of an animal by contacting the oral care compositions with at least one surface of the oral cavity.

The invention provides a wound hemostasis device for the emergency department, and relates to the technical field of wound hemostasis. The wound hemostasis device for the emergency department comprises an inflatable hemostasis air bag, and a constant-temperature film bag is fixedly connected to the lower surface of the inflatable hemostasis air bag. During working, a second infusion pump is started and pumps water in a constant-temperature water storage tank through a second infusion pipeline, the water enters a constant-temperature film bag through a fourth infusion pipeline, the temperature of a wound is guaranteed, meanwhile, a first infusion pump is started, a first water valve on a first infusion pipeline is opened, and a second water valve on a second infusion pipeline is opened. Water in the constant-temperature film bag is pumped through the first liquid pumping pipeline, and finally the water enters the constant-temperature water storage tank, so that the water in the constant-temperature film bag is always in a constant-temperature state, the temperature is ensured to be close to the optimum point of thrombin reaction, platelet aggregation and fibrin formation can be accelerated, and the method is safe and efficient, can minimize tissue damage, and is suitable for clinical application. And the hemostasis speed is accelerated.

The invention discloses combined probiotics for improving sarcopenia as well as a preparation method and application of the combined probiotics, and belongs to the field of probiotics. The invention relates to a combined probiotic for improving sarcopenia. The combined probiotic comprises a lactobacillus reuteri body, a lactobacillus johnsonii body, a lactobacillus fermentum body and a bifidobacterium adolescentis body. The combined probiotics disclosed by the invention can be used for remarkably improving the overall symptoms of sarcopenia model mice, including inhibiting weight loss, constipation symptoms and colonic mucosa destruction, prolonging load swimming time, improving muscle endurance, improving skeletal muscle atrophy, improving the expression of I-type slow muscle fiber protein MyHC I and promoting slow muscle fiber repair, and has the effects of preventing and treating sarcopenia. The invention discloses a probiotic intervention method for treating sarcopenia, which comprises the following steps of: preparing probiotics for treating sarcopenia, reducing the content of inflammatory cytokines in muscular tissues, increasing the content of hepatic glycogen, improving systematic metabolism of mice with sarcopenia and damaged serum markers, including lactic acid, lactic dehydrogenase, creatine kinase, creatinine, alanine transaminase ALT and aspartate transaminase AST, providing a new scheme for probiotic intervention for sarcopenia, and being used for preparing related functional products or intervention means.

A fibrillin production promoter contains at least one pyrimidine nucleotide or precursor thereof as an active ingredient.

In one aspect, the invention provides compositions and methods for preventing, reducing, and / or treating a disease, disorder or condition associated with fibrin-induced activation of the complement system and the associated activation of the coagulation and / or contact systems comprising administering a therapeutic amount of a MASP-2 inhibitory antibody to a subject in need thereof. In some embodiments, the methods of the invention provide anticoagulation and / or antithrombosis and / or antithrombogenesis without affecting hemostasis. In one embodiment of this aspect of the invention, the compositions and methods are useful for treating a subject is suffering from, or at risk of developing, a disease, disorder or condition associated with complement-related inflammation, excessive coagulation or contact system activation initiated by fibrin or activated platelets.

Disclosed is a method for filtering a fibrinogen composition, including the following steps: a) purifying the fibrinogen composition by chromatographic purification using an elution buffer comprising arginine; b) optionally, at least one step of filtering the fibrinogen composition obtained by chromatographic elution in step a), on a filter having a pore size of between 0.08 μm and 0.22 μm, c) filtering the fibrinogen composition obtained by chromatographic elution in step a), or optionally obtained in step b), on a symmetrical filter having a pore size of between 15 nm and 25 nm, and preferably between 18 nm and 22 nm, and d) recovering the resulting fibrinogen solution, the filtering method being carried out without adding arginine after step a), at a high capacity and without a prior freezing and / or thawing step.

A system for determining a functional fibrinogen concentration from a patient's coagulating blood or blood plasma sample is configured to obtain a signal representing physical or biochemical properties of the developing fibrin network during coagulation of the patient's blood or blood plasma sample over time, determine the fibrinogen concentration based on one or more values of one or more features of the signal with the help of a learned function which maps values of the feature(s) to functional fibrinogen concentrations, and output the fibrinogen concentration, e.g. on a display. The feature(s) include(s) multiple of features related to 1) a maximum value of the gradient of the signal, 2) the maximum of the second derivative of the signal, 3) a difference between the maximum and the minimum of the signal, and 4) the minimum of the second derivative of the signal, or at least feature 1) or 2).

Provided are polynucleotides comprising a mobile bacterial island nucleotide sequence (B-INS) comprising one or more modifications (a modified B-INS) that include deletion or modification of restriction enzyme recognition sites to inhibit restriction enzyme cleavage of the B-INS, and an insertion of at least one cargo sequence into the B-INS. The B-INS is packaged within a bacterium into a phage-like particle that contains a bacteriophage capsid, tail and tail fiber proteins. The phage-like particle function as an antibacterial drone "ABD" and infects bacteria. The cargo sequence is introduced into bacteria infected by the ABD and kills the infected bacteria or inhibits growth of infected bacteria.

The invention provides plasmin-targeted complement C3 derived anticoagulant polypeptide and application thereof, and belongs to the technical field of biological medicine. The present invention provides a complement C3-derived anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10), which reduce nerve injury by enhancing the activity of plasmin in degrading fibrin thrombus and promoting the production of matBDNF (matured brain-derived neurotrophic factor), thereby protecting a host from dual threats of inflammatory thrombosis and neurological dysfunction, and also provides a method for preparing the anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10). And good safety is shown. In conclusion, it is found for the first time that the complement C3 polypeptides C3-HK10 and C3-moHK10 have the characteristic of promoting plasmin activity, have the functions of inhibiting inflammation, thrombus and ischemic cerebral apoplexy injury and relieving nerve injury, and have the potential of becoming anti-inflammatory, thrombus and stroke treatment and neurological function drugs.

An example system for detecting and quantifying drug and / or chemical interactions with a biological sample is provided. The system includes a detection instrument with computing capability. The system includes an assay device capable of receiving a biological sample. Introduction of the biological sample into the assay device results in a biological process by which fibrin and platelets may accumulate at a reaction zone of the assay device. The assay device is capable of receiving one or more chemical reagents and one or more drug reagents. The fibrin and platelets, and their associated signals, accumulated at the reaction zone of the assay device are usable to determine at least one of a drug presence, a drug class, a drug level in relation to a threshold, or a drug concentration, within the biological sample.

The invention discloses a preparation method of a fibrous protein / bacterial cellulose efficient hemostatic patch. The preparation method comprises the following steps: (1) in-situ preparation of large-aperture bacterial cellulose; (2) infiltration of fibrinogen in the large-aperture bacterial cellulose; and (3) enzyme digestion and freeze-drying treatment of fibrinogen. The problems that fibrinogen is fast in degradation and poor in stability and mechanical property are solved, the prepared fibrous protein / bacterial cellulose efficient hemostatic patch can prevent secondary bleeding and avoid thrombus to a certain extent, the preparation process is simple and easy to implement, and large-scale preparation and storage can be achieved.

The present disclosure provides a catheter system including a plurality of fenestrations along the shaft of the catheter, wherein the fenestrations allow for continuous or intermittent infusion of antiseptics and / or antibiotics to avoid and treat bacterial colonization or infection of the subcutaneous tract and to minimize subcutaneous tunnel colonization and fibrin sheath in symptomatic or asymptomatic patients. The present catheter system can also include a removable abrasive component on the catheters tip to assist with mechanical debridement of subcutaneous tract and intravascular fibrin sheath.

This invention discloses a method for preparing a composite spray that improves hemostasis at wound sites. The composite spray includes solution A and solution B, where solution B is an aqueous solution of sodium alginate. The preparation method of solution A includes: 1. Dissolving a lipopeptide conjugate, cholesterol, distearylphosphatidylcholine, distearylphosphatidylserine, and dimethyl sulfoxide in a chloroform-methanol mixed solution to obtain a mixed system; 2. Preparing a precursor solution from the mixed system using a thin-film hydration method; 3. Adding calcium chloride to the precursor solution and reacting it in the dark to obtain solution A. This invention designs the precursor solution based on the function of natural platelets, and its function is equivalent to that of nanoplatelets. Combined with sodium alginate, it can specifically alleviate the adverse effects on the coagulation system caused by blood loss, such as fibrin degradation and reduced platelet activation, at wound sites. It has the characteristics of rapid hemostasis, good bioactivity, and rapid wound healing.

The invention provides an anti-coagulation coating. The anti-coagulation coating comprises an anti-coagulation component and a cross-linking agent, the preparation method of the anti-coagulation coating comprises the following steps: plasma activation: carrying out surface activation treatment on the surface of the conduit by adopting plasma; preparing a surface anti-coagulation coating: firstly preparing an anti-coagulation solution, immersing the catheter in the anti-coagulation solution containing phosphorylcholine, placing the catheter at room temperature after dip-coating, then placing the catheter in a curing box for curing, and taking out the catheter after the catheter is cooled to the room temperature, so as to prepare the catheter with the anti-coagulation coating containing phosphorylcholine; according to the anticoagulant coating, complications such as thrombus and fibrin sheath are reduced, the safety of a product is improved, anaphylactic reaction caused by drugs and heparin is avoided, and a passive anticoagulation mode is adopted, so that the blood coagulation capacity of a patient cannot be reduced, and the risk that a wound cannot be healed can be effectively reduced.

The utility model discloses a hemostasis assist device for vascular surgery, which relates to the technical field of medical instruments, and comprises a fixing mechanism, a vascular surgery hemostasis mechanism is arranged in the fixing mechanism, the vascular surgery hemostasis mechanism comprises a knob, and the bottom of the knob is fixedly connected with a threaded column. According to the hemostasis mechanism for the vascular surgery department, during hemostasis, the periphery of a wound can be heated through the heating block across the replacement pad, the temperature of the periphery of the wound reaches 37-42 DEG C, activation of platelets can be accelerated to a certain extent at the temperature, energy metabolism of the platelets is accelerated within the temperature range, and the blood circulation is accelerated. The increase of the concentration of calcium ions in the blood platelets is an important signal of platelet activation, and the increased concentration of the calcium ions can promote the activation of glycoprotein receptors on platelet membranes, so that the binding capacity of the blood platelets and fibrinogen is enhanced, the aggregation of the blood platelets is accelerated, and the hemostasis speed is accelerated.

The invention relates to the technical field of electrochemical sensing, in particular to a multi-channel electrochemical aptamer sensor and a preparation method and application thereof.The multi-channel electrochemical aptamer sensor adopts a commercial silk-screen printing electrode and is combined with a polymer substrate material for amplifying electrochemical signals, and the electrochemical aptamer sensor is prepared. According to the present invention, the corresponding aptamer is fixed by using the gold nanoparticle through the chemical bond so as to specifically detect the three hemorrhage conversion biomarkers after acute cerebral infarction, such as human matrix metalloproteinase (MMP-9), fibrinogen (FN) and plasminogen activation inhibitor (PAI-1); wherein the FN and the PAI-1 are detected through an electrochemical aptamer sensor method for the first time, and simultaneous detection of the three biomarkers is realized through integration with commercial multi-channel micro electrochemical equipment.

The present application relates to the technical field of in vitro detection, and particularly relates to a platelet aggregation function detection reagent and application thereof.The platelet aggregation function detection reagent provided by the present application comprises a fibrin activator and an ADP reagent, the fibrin activator adopts a novel high-purity porcine dermal collagen polypeptide component Prionex, and the combination with glycine significantly improves the stability of the fibrin activator, the platelet inhibitor tirofiban is used in combination with PEG6000, the accuracy of the detection result is improved, and the sensitivity to the anti-platelet aggregation drug is improved; the ADP reagent adopts chitosan, the activity and stability are improved, and the ADP reagent can be widely applied to clinical diagnosis of platelet aggregation function.

The invention relates to the technical field of biomedical materials and tissue engineering, and discloses sequential slow-release temperature-sensitive hydrogel and a preparation method and application thereof.The preparation method comprises the following steps that a blood sample is subjected to programmed centrifugation, and a gel layer of leukocyte-rich platelet-rich fibrin L-PRF and a gel layer of improved platelet-rich fibrin A-PRF are obtained respectively; and the gel layer is cut into pieces, pre-frozen, freeze-dried, ground and sieved, so that L-PRF freeze-dried powder and A-PRF freeze-dried powder are obtained respectively, and the methacrylic acid gelatin microspheres entrapped with the L-PRF freeze-dried powder are prepared. The microspheres and A-PRF freeze-dried powder are loaded into a temperature-sensitive hydrogel system composed of chitosan, polygalacturonic acid and sodium beta-glycerophosphate, so that the growth factors can be effectively entrapped in the hydrogel structure, and continuous release is realized; the system has good mechanical strength and structural stability, the retention time of the material in vivo is prolonged, and stable three-dimensional network support is provided.

The present invention relates to a method for the preparation of an assembly of cells and microrobots comprising (a) preparing a suspension of cells and microrobots, wherein the microrobots comprises an alginate, collagen, fibrin, hyaluronic acid / collagen, polyacrylamide, or polyethylene glycol hydrogel capsule, wherein the alginate is conjugated to cell adhesive peptides, and (b) incubating the suspension of (a) to allow the microrobots to form an assembly with the cells via the binding of the cell adhesive peptides to the cells, wherein step (b) and preferably steps (a) and (b) are performed in a conic microcentrifuge tube with a rounded bottom without corners and edges.

The present application relates to a method for preparing and expanding a TSCM cell in vitro. Specifically, the method comprises: 1) obtaining an isolated CD8+ T cell; 2) activating the CD8+ T cell; 3) mixing the activated CD8+ T cell, a fibrinogen solution and a thrombin solution, and culturing same under conditions suitable for cell growth, so as to obtain a TSCM cell culture; and 4) bringing the culture into contact with a dispase so as to obtain a TSCM cell. The present application also relates to a kit for preparing and expanding a TSCM cell in vitro, the use of fibrinogen and thrombin in the preparation of a kit for preparing and expanding a TSCM cell in vitro, and a TSCM cell obtained by means of the method or kit of the present application.

To provide compositions containing RPE cells or RPE monolayers, as well as methods and materials for making RPE cells or RPE monolayers from, for example, stem cells (e.g., iPSCs).SOLUTION: Disclosed is a method for making a retinal pigment epithelium monolayer, the method comprising, or consisting essentially of, culturing stem cells in a container having a surface coated with fibrinogen, wherein the surface is coated with greater than 3 μg / mL of fibrinogen, wherein the cells are in contact with the fibrinogen, and wherein the cells form the retinal pigment epithelium monolayer.SELECTED DRAWING: None

The application belongs to the technical field of in-vitro diagnostic reagents, and particularly relates to thrombelastography quality control products and a preparation method and application in preparation of coagulation detection products, a coagulation detection product and a coagulation detection method. The application realizes high adhesion of quality control product coagulation parameters and clinical actual measurement values by optimizing plasma proportioning and screening special excipients, can simulate six typical clinical coagulation states from normal coagulation to low coagulation, high coagulation, fibrinogen abnormality, DIC and the like, and simultaneously has the characteristics of simple preparation process and excellent long-term stability.

The invention belongs to the technical field of biomedical material engineering, and discloses a hydrogel scaffold used for 3D tumor sphere culture and drug screening, the scaffold is formed by four-arm polyethylene glycol maleimide, fibrinogen and thrombin through Michael addition crosslinking and biopolymerization synergistically, the elastic modulus of 10-1000 Pa can be adjusted by regulating and controlling the proportion of all the components, and the hydrogel scaffold can be used for 3D tumor sphere culture and drug screening. Gel forming is completed within 5 min at the room temperature. The scaffold has the biological activity of fibrous protein and the structural stability of polyethylene glycol, can efficiently support HCT116 cells to form high-activity tumor balls, accurately simulate the in-vivo tumor microenvironment and remarkably improve the accuracy and repeatability of drug screening, is easy and convenient to operate, is compatible with a standard pore plate high-throughput platform and is suitable for drug sensitivity detection of personalized treatment of tumors.

Disclosed herein are low density particles comprising polymerized fibrin that are micrometer or nanometer sized in diameter. The particles can further include at least one therapeutic agent. The particles may be used to treat wounds, by administration directly or systemically to the site of the wound. Exemplary wounds that may be treated with the fibrin particles include a trauma wound, a surgical wound, a burn wound, or an ulcer wound. Also disclosed herein are methods for preparing the particles using a shearing process.

The present invention provides for a novel method for the detection of the presence of myasthenia gravis in a subject, by means of detecting the presence of fibrinogen in serum generated from the blood of the patient. Further novel means for stabilizing the fibrinogen, for the purposes of interrogation of the sample, are provided.

A bio-ink comprising: (a) at least one polysaccharide; (b) at least one structural protein; and (c) fibrinogen, wherein the polysaccharide is selected from a group consisting of Sodium alginate Chitosan, Hyaluronic acid, Gellan gum, Dextran, Agarose, Poly(ethylene glycol), Pluronic and Carrageenan and the structural protein is selected from a group consisting of Gelatin, Collagen Vitronectin, Laminins and Fibronectin.

Described herein are multi-specific antigen-binding proteins that bind human fibrin γC or fibrinogen γC domain and vascular endothelial growth factor, and methods of use thereof. In some embodiments, described herein are pharmaceutical compositions comprising the multi-specific antigen-binding proteins that bind fibrin γC or fibrinogen γC domain and vascular endothelial growth factor. In some embodiments, the multi-specific antigen-binding proteins and methods described herein are used for treatment of disorders or conditions of the eye.

The invention relates to a method for determining a fibrinogen concentration in a blood sample, comprising whole blood, the sample having been mixed with a reagent configured to cause fibrin formation, the method comprising: - a) forming images (I(t)) of the sample at various times (t); - b) establishing a correlation indicator (C(t)) between images acquired at various respective times (I(t), (I(t + dt))); - c) determining a variation as a function of time in the correlation indicator; - d) detecting a coagulation time (tcoag) on the basis of the variation as a function of time; - e) depending on the coagulation time, determining the fibrinogen concentration in the blood; the method being characterised in that: the reagent comprises batroxobin, the batroxobin concentration, after mixing, being between 25 and 1000 enzyme units per mL.